Levetiracetam in combined therapy for focal epilepsy: Experience with 80 patients;Levetiracetam in der kombinationsbehandlung fokaler epilepsien: Erfahrungen bei 80 patienten

Nervenarzt

Volumn 75, Issue 8, 2004, Pages 749-754

  Schulze Bonhage, A ^a   Feil, B ^a   Fauser, S ^a   Homberg, V ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Combination therapy; Efficacy; Focal epilepsy; Levetiracetam; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADD ON THERAPY; AGGRESSIVENESS; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXPERIENCE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; SEIZURE; SOMNOLENCE; TITRIMETRY;

ADULT; ANTICONVULSANTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; PIRACETAM; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 4344590325     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. -1 in adult patients with refractory epilepsy. Seizure 12:141-149
2. Bazil CW, Rose A, Resor S et al. (2002) Levetiracetam may be more effective for late-onset partial epilepsy. Arch Neurol 59:1905-1908
3. Bello-Espinosa LE, Roberts SL (2003) Levetiracetam for benign epilepsy of childhood with centrotemporal spikes - three cases. Seizure 12:157-159
4. Ben-Menachem E, Falter U (2000) Efficacy and tolerability of levetiracetam 3,000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41:1276-1283
5. Ben-Menachem E, Edrich P, van Vleymen B et al. (2003) Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53:57-64
6. Betts T, Waegemans T, Crawford P (2000) A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000 mg daily and 4,000 mg daily, without titration in patients with refractory epilepsy. Seizure 9:80-87
7. Betts T, Yarrow H, Greenhill L et al. (2003) Clinical experience of marketed Levetiracetam in an epilepsy clinic - a one year follow up study. Seizure 12:136-140
8. Bialer M, Johannessen SI, Kupferberg HJ et al. (2002) Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 51:31-71
9. Boon P, Chauvel P, Pohlmann-Eden B et al. (2002) Dose-response effect of levetiracetam 1,000 and 2,000 mg/ day in partial epilepsy. Epilepsy Res 48:77-89
10. Cereghino JJ, Biton V, Abou-Khalil B et al. (2000) Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trial. Neurology 55:236-242
11. Cohen J (2003) Levetiracetam monotherapy for primary generalised epilepsy. Seizure 12:150-153
12. Cramer JA, DeRue K, Devinsky O et al. (2003) A systematic review of the behavioural effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epil Behav 4:124-132
13. Dinkelacker V, Dietl T, Widman G et al. (2003) Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epil Behav 4:537-547
14. French J, Edrich P, Cramer JA (2001) A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 47:77-90
15. Gates JR, Folland C, Berhovw J et al. (2002) Behavioral side-effects of levetiracetam. Epilepsia 43(S7):187
16. Gelisse P, Crespel A, Genton P et al. (2003) Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 107:302-303
17. Glauser TA, Pellock JM, Bebin EM et al. (2002) Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43:518-524
18. Glien M, Brandt C, Potschka H et al. (2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43:350-357
19. Gower AJ, Hirsch E, Boehrer A et al. (1995) Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22:207-213
20. Grant R, Shorvon SD (2000) Efficacy and tolerability of 1,000-4,000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res 42:89-95
21. Harden C (2001) Safety profile of levetiracetam. Epilepsia 42(S4):36-39
22. Klitgaard H, Matagne A, Gobert J et al. (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353:191-206
23. Kossoff EH, Bergey GK, Freeman J et al. (2001) Levetiracetam psychosis in children with epilepsy. Epilepsia 42:1611-1613
24. Krakow K, Walker M, Otoul C et al. (2001) Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56:1772-1774
25. Löscher W, Hönack D (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232:147-158
26. Matagne AC, Baltes E, Coupez R et al. (2001) Levetiracetam enhances markedly the seizure suppression of other antiepileptic drugs in audiogenic susceptible mice. Epilepsia 42(S7):82
27. Morrell MJ, Leppik I, French J et al. (2003) The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54:153-161
28. Noyer M, Gillard M, Matagne A et al. (1995) The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286:137-146
29. Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: towards ideal characteristics. Pharmacol Therap 85:77-85
30. Perrucca E, Gidal BE, Baltès E (2003) Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive theapy trials. Epilepsy Res 53:47-56
31. Rijckevorsel K (2001) The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 10:235-26
32. Sadek A, Fix A, French J (2002) Levetiracetam-related behavioural adverse effects: a post-marketing study. Epilepsia 43(S8):151
33. Schmidt D, Elger CE, Holmes GL (2002) Pharmacological over-treatment in epilepsy. Epilepsy Res 51:1-12
34. Sharief M, Singh P, Sander J et al. (1996) Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 9:106-112
35. Shorvon SD, Löwenthal A, Janz D et al. (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41:1179-1186
36. Walker MC, Patsalos PN (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 67:351-384
37. White JR, Walczak TS, Leppik IE et al. (2003) Discontinuation of levetiracetam because of behavioural side effects. Neurology 61:1218-1221
38. 2+ currents. Seizure 10:279-286